Veracyte Q2 revenue rises 14% to $130.2M; testing revenue guidance raised
Veracyte reported second-quarter 2025 total revenue of $130.2 million, up 14% year over year, and swung to a GAAP net loss of $1.0 million after a $20.5 million impairment tied to its French subsidiary. The company raised its full-year testing revenue guidance and initiated full-year total revenue guidance of $496 million to $504 million, which matters to shareholders because it signals higher expected sales while the one-time charge weighs on reported profit.
Key points
- Q2 2025 total revenue was $130.2 million, up 14% from $114.4 million; testing revenue was $122.3 million, up 14%.
- GAAP net loss was $1.0 million, compared with net income of $5.7 million in Q2 2024, including a $20.5 million impairment charge.
- Full-year 2025 testing revenue guidance was raised to $477 million to $483 million from $470 million to $480 million; total revenue guidance is $496 million to $504 million.
- Non-GAAP diluted EPS was $0.44, up from $0.30 a year earlier; adjusted EBITDA was $35.8 million, or 27.5% of revenue.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:55 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.